Background: ERâŁ36 is present in ERâŁ-negative breast cancer and mediates rapid responses. Results: Estrogen promoted cell survival and increased metastatic factors in breast cancer through membrane ERâŁ36. Conclusion: ERâŁ36 plays a major role in estrogen responses of ERâŁ-negative breast cancers. Significance: Examining the role of ERâŁ36 in ERâŁ-negative breast cancer is essential for understanding the negative effects of estrogen in breast cancer.Protein kinase C (PKC) signaling can be activated rapidly by 17â€-estradiol (E 2 ) via nontraditional signaling in ERâŁ-positive MCF7 and ERâŁ-negative HCC38 breast cancer cells and is associated with tumorigenicity. Additionally, E 2 has been shown to elicit anti-apoptotic effects in cancer cells counteracting pro-apoptotic effects of chemotherapeutics. Supporting evidence suggests the existence of a membraneassociated ER that differs from the traditional receptors, ER⣠and ERâ€. Our aim was to identify the ER responsible for rapid PKC activation and to evaluate downstream effects, such as proliferation, apoptosis, and metastasis. RT-PCR, Western blot, and immunofluorescence were used to determine the presence of ER splice variants in multiple cell lines. E 2 effects on PKC activity were measured with and without ER-blocking antibodies. Cell proliferation was determined by [ 3 H]thymidine incorporation, and cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, (MTT) whereas apoptosis was determined by DNA fragmentation and TUNEL. Quantitative RT-PCR and sandwich ELISA were used to determine the effects on metastatic factors. The role of membrane-dependent signaling in cancer cell invasiveness was examined using an in vitro assay. The results indicate the presence of an ER⣠splice variant, ERâŁ36, in ERâŁ-positive MCF7 and ERâŁ-negative HCC38 breast cancer cells, which localized to plasma membranes and rapidly activated PKC in response to E 2 , leading to deleterious effects such as enhancement of proliferation, protection against apoptosis, and enhancement of metastatic factors. These findings propose ERâŁ36 as a novel target for the development of therapies that can prevent progression of breast cancer in the primary tumor as well as during metastasis.The complexities of breast cancer growth and metastasis present several problems in development of treatments for patients. The main screening process in determining the treatment and prognosis of breast cancer patients is receptor status. Growth of estrogen receptor (ER) 2 -positive breast cancers is typically enhanced by estrogen, but ER interactions with DNA are not necessary for this growth to occur (1, 2), suggesting that non-nuclear actions of ERs may play a role. Triple negative breast cancers, which are ER-negative, progesterone receptornegative, and human epidermal growth factor receptor 2 (HER2)-negative, are typically characterized as more aggressive and less responsive to hormone treatments (3). These tumors are also less responsive to treatments such as tamoxifen, a commonly used ...